Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of E7070 in patients with metastatic melanoma.
Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ; EORTC New Drug Development and Melanoma Groups. Smyth JF, et al. Among authors: lesimple t. Ann Oncol. 2005 Jan;16(1):158-61. doi: 10.1093/annonc/mdi016. Ann Oncol. 2005. PMID: 15598954 Free article. Clinical Trial.
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.
Charton E, Baldini C, Fayet Y, Schultz E, Auroy L, Vallier E, Italiano A, Robert M, Coquan E, Isambert N, Moreau P, Touzeau C, Le Tourneau C, Ghrieb Z, Kiladjian JJ, Delord JP, Gomez Roca C, Vey N, Barlesi F, Lesimple T, Penel N, Soria JC, Massard C, Besle S. Charton E, et al. Among authors: lesimple t. ESMO Open. 2023 Aug;8(4):101610. doi: 10.1016/j.esmoop.2023.101610. Epub 2023 Aug 1. ESMO Open. 2023. PMID: 37536254 Free PMC article.
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C, Douillard JY, Caty A, Geoffrois L, Ferrero JM, Linassier C, Drevon M, Négrier S. Ravaud A, et al. Among authors: lesimple t. J Clin Oncol. 1998 Aug;16(8):2728-32. doi: 10.1200/JCO.1998.16.8.2728. J Clin Oncol. 1998. PMID: 9704724 Clinical Trial.
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
Négrier S, Caty A, Lesimple T, Douillard JY, Escudier B, Rossi JF, Viens P, Gomez F. Négrier S, et al. Among authors: lesimple t. J Clin Oncol. 2000 Dec 15;18(24):4009-15. doi: 10.1200/JCO.2000.18.24.4009. J Clin Oncol. 2000. PMID: 11118461 Clinical Trial.
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
Raymond E, Campone M, Stupp R, Menten J, Chollet P, Lesimple T, Fety-Deporte R, Lacombe D, Paoletti X, Fumoleau P; EORTC Early Clinical Studies Group (ECSG); Brain Tumor Studies Group (BTSG); New Drug Development Program (NDDP). Raymond E, et al. Among authors: lesimple t. Eur J Cancer. 2002 Jul;38(10):1348-50. doi: 10.1016/s0959-8049(02)00070-9. Eur J Cancer. 2002. PMID: 12091065 Clinical Trial.
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.
van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, Dittrich C, de Jonge MJ, Brandes A, Frenay M, Carpentier AF, Chollet P, Oliveira J, Baron B, Lacombe D, Schuessler M, Fumoleau P; European Organization for Research and Treatment of Cancer New Drug Development Group; European Organization for Research and Treatment of Cancer Brain Tumor Group. van den Bent MJ, et al. Among authors: lesimple t. Ann Oncol. 2003 Dec;14(12):1732-4. doi: 10.1093/annonc/mdg491. Ann Oncol. 2003. PMID: 14630677 Free article. Clinical Trial.
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Fumoleau P, Largillier R, Clippe C, Dièras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Curé H, Vuillemin E, Morère JF, Montestruc F, Mouri Z, Namer M. Fumoleau P, et al. Among authors: lesimple t. Eur J Cancer. 2004 Mar;40(4):536-42. doi: 10.1016/j.ejca.2003.11.007. Eur J Cancer. 2004. PMID: 14962720 Clinical Trial.
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Davies MA, et al. Among authors: lesimple t. Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4. Lancet Oncol. 2017. PMID: 28592387 Free PMC article. Clinical Trial.
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV. Schadendorf D, et al. Among authors: lesimple t. Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27. Lancet Oncol. 2019. PMID: 30928620 Clinical Trial.
132 results